Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAdR for Relapsed/Refractory T-cell Malignancies
NCT04447027Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lenalidomide in mature T-cell neoplasm (PTCL) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 21 days and Rate and Severity of Serious and/or Non-serious Adverse Events. Started Dec 2020; status: completed.
02
Drugs
lenalidomide
03
Conditions
mature T-cell neoplasm (PTCL)
Beyond the preview
Go deeper on NCT04447027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447027.